Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $279M (up 11.3% year over year) with net income of $72M.
Q3 2025 key financials · XBRL
- Revenue
- $279M
- +11.3% YoY · +5.3% QoQ
- Net income
- $72M
- +119.1% YoY · +169.2% QoQ
- Operating margin
- 12.8%
- EPS (diluted)
- $0.42
- +110.0% YoY · +162.5% QoQ
Source: XBRL data from the ACADIA PHARMACEUTICALS INC (ACAD) Q3 2025 10-Q on SEC EDGAR. USD.
ACADIA PHARMACEUTICALS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: January 2025 EU HTA Regulation No 2021/2282 requires joint clinical assessments impacting trofinetide pricing and reimbursement
- Updated product acceptance risk: DAYBUE approved October 2024 in Canada; reliance on patient adherence and physician prescribing for Rett syndrome sales
- Regulatory compliance risk: ongoing DAYBUE post-marketing requirements with one PMR released and three fulfilled, FDA may require label updates or risk mitigation
- Operational market risk: dependence on limited third-party specialty distributors and pharmacies for U.S., Canada, and future markets poses commercialization vulnerability
- Financial risk: ongoing need for additional financing to support operations and research with no guarantee of availability impacting funding of development programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACADIA PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.